Neumora Therapeutics (NASDAQ:NMRA) Announces Quarterly Earnings Results

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02, FiscalAI reports.

Neumora Therapeutics Price Performance

NASDAQ NMRA opened at $0.43 on Monday. Neumora Therapeutics has a 12 month low of $0.32 and a 12 month high of $3.65. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.50 and a quick ratio of 4.50. The company’s 50 day simple moving average is $0.60 and its 200 day simple moving average is $1.70. The firm has a market capitalization of $80.59 million, a PE ratio of -0.35 and a beta of 3.12.

Insiders Place Their Bets

In other news, insider Daljit Singh Aurora sold 21,055 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $1.60, for a total transaction of $33,688.00. Following the completion of the transaction, the insider owned 48,750 shares in the company, valued at approximately $78,000. This trade represents a 30.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders have sold 307,127 shares of company stock valued at $481,160. 26.94% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NMRA. HC Wainwright reaffirmed a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Wall Street Zen upgraded Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, November 7th. Finally, Weiss Ratings upgraded shares of Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.57.

Get Our Latest Stock Analysis on NMRA

About Neumora Therapeutics

(Get Free Report)

Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. Founded in 2020 and headquartered in Watertown, Massachusetts, the company researches potential medicines for conditions including depression, schizophrenia and agitation associated with Alzheimer’s disease. The company combines neuroscience research with data science and other computational approaches to identify disease targets and develop drug candidates. Its pipeline includes investigational medicines designed to act on specific biological pathways involved in brain disorders; these products are under development and are not approved treatments.

Featured Stories

Earnings History for Neumora Therapeutics (NASDAQ:NMRA)

Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.